Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.71
USD
|
+0.59%
|
|
+1.79%
|
-20.83%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
599.6
|
1,157
|
1,173
|
647.6
|
391.4
|
316.2
|
-
|
-
|
Enterprise Value (EV)
1 |
599.6
|
1,157
|
1,173
|
647.6
|
391.4
|
316.2
|
316.2
|
316.2
|
P/E ratio
|
-8.27
x
|
-18.7
x
|
-21.3
x
|
-15.2
x
|
-10.3
x
|
-15.5
x
|
-34.2
x
|
-34.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.03
x
|
12.6
x
|
8.96
x
|
4
x
|
2.5
x
|
1.77
x
|
1.56
x
|
1.46
x
|
EV / Revenue
|
8.03
x
|
12.6
x
|
8.96
x
|
4
x
|
2.5
x
|
1.77
x
|
1.56
x
|
1.46
x
|
EV / EBITDA
|
-9.39
x
|
-20.9
x
|
-25.6
x
|
-52
x
|
-36.5
x
|
48.7
x
|
21.4
x
|
12.5
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-11.3
x
|
-13.2
x
|
31.6
x
|
16.9
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-8.83%
|
-7.56%
|
3.16%
|
5.91%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
142,089
|
167,142
|
172,266
|
177,421
|
181,197
|
184,890
|
-
|
-
|
Reference price
2 |
4.220
|
6.920
|
6.810
|
3.650
|
2.160
|
1.710
|
1.710
|
1.710
|
Announcement Date
|
2/20/20
|
2/25/21
|
2/22/22
|
2/28/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
74.65
|
91.92
|
130.9
|
162
|
156.4
|
178.7
|
202.8
|
216.8
|
EBITDA
1 |
-63.82
|
-55.22
|
-45.79
|
-12.45
|
-10.72
|
6.494
|
14.8
|
25.3
|
EBIT
1 |
-66.23
|
-58.33
|
-48.94
|
-34.08
|
-30.05
|
-13.45
|
-3.008
|
-
|
Operating Margin
|
-88.72%
|
-63.46%
|
-37.4%
|
-21.03%
|
-19.22%
|
-7.53%
|
-1.48%
|
-
|
Earnings before Tax (EBT)
1 |
-70.98
|
-59.57
|
-54.06
|
-42.34
|
-37.32
|
-19.89
|
-9.442
|
-
|
Net income
1 |
-71.24
|
-59.86
|
-54.37
|
-42.78
|
-37.49
|
-20.05
|
-9.844
|
-
|
Net margin
|
-95.44%
|
-65.12%
|
-41.55%
|
-26.4%
|
-23.98%
|
-11.22%
|
-4.85%
|
-
|
EPS
2 |
-0.5100
|
-0.3700
|
-0.3200
|
-0.2400
|
-0.2100
|
-0.1100
|
-0.0500
|
-0.0500
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-34.54
|
-23.9
|
10
|
18.7
|
FCF margin
|
-
|
-
|
-
|
-
|
-22.09%
|
-13.37%
|
4.93%
|
8.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
67.54%
|
73.91%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
2/25/21
|
2/22/22
|
2/28/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
36.13
|
39.86
|
37.44
|
41
|
39.57
|
44.03
|
30.97
|
38.85
|
39.77
|
46.77
|
38.35
|
44.33
|
45.65
|
50.39
|
40.9
|
EBITDA
1 |
-
|
-6.15
|
-3.661
|
-2.414
|
-2.676
|
-3.699
|
-9.754
|
-4.74
|
-0.972
|
4.743
|
-1.917
|
1.199
|
1.773
|
5.439
|
-1.792
|
EBIT
1 |
-11.13
|
-6.962
|
-9.848
|
-6.835
|
-7.447
|
-9.951
|
-14.15
|
-9.512
|
-5.243
|
0.976
|
-7.258
|
-4.15
|
-2.933
|
0.9264
|
-7.722
|
Operating Margin
|
-30.79%
|
-17.46%
|
-26.3%
|
-16.67%
|
-18.82%
|
-22.6%
|
-45.67%
|
-24.48%
|
-13.18%
|
2.09%
|
-18.93%
|
-9.36%
|
-6.43%
|
1.84%
|
-18.88%
|
Earnings before Tax (EBT)
1 |
-12.36
|
-9.05
|
-12.21
|
-8.317
|
-8.454
|
-13.36
|
-15.56
|
-13.23
|
-7.208
|
-1.317
|
-8.882
|
-5.753
|
-4.537
|
-0.6772
|
-9.095
|
Net income
1 |
-12.44
|
-9.119
|
-12.28
|
-8.389
|
-8.482
|
-13.62
|
-15.62
|
-13.28
|
-7.267
|
-1.328
|
-8.917
|
-5.809
|
-4.592
|
-0.7126
|
-9.12
|
Net margin
|
-34.42%
|
-22.87%
|
-32.81%
|
-20.46%
|
-21.43%
|
-30.94%
|
-50.43%
|
-34.17%
|
-18.27%
|
-2.84%
|
-23.25%
|
-13.1%
|
-10.06%
|
-1.41%
|
-22.3%
|
EPS
2 |
-0.0700
|
-0.0500
|
-0.0700
|
-0.0600
|
-0.0500
|
-0.0800
|
-0.0900
|
-0.0700
|
-0.0400
|
-0.0100
|
-0.0480
|
-0.0300
|
-0.0240
|
-0.004000
|
-0.0500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/21
|
2/22/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/28/23
|
5/4/23
|
8/2/23
|
11/2/23
|
3/5/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-34.5
|
-23.9
|
10
|
18.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
8.94
|
1.62
|
0.91
|
2
|
4.6
|
8.5
|
9.6
|
9.6
|
Capex / Sales
|
11.97%
|
1.76%
|
0.7%
|
1.23%
|
2.94%
|
4.76%
|
4.73%
|
4.43%
|
Announcement Date
|
2/20/20
|
2/25/21
|
2/22/22
|
2/28/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
1.71
USD Average target price
4.2
USD Spread / Average Target +145.61% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.83% | 316M | | +12.07% | 128B | | -9.04% | 10.65B | | +0.91% | 8.82B | | +16.72% | 7.19B | | +25.15% | 4.99B | | +7.17% | 3.4B | | -1.36% | 3.03B | | -8.73% | 2.14B | | -10.15% | 2B |
Medical Devices & Implants
|